Anoro Ellipta

This page shows the latest Anoro Ellipta news and features for those working in and with pharma, biotech and healthcare.

Sovaldi pushes Gilead to the top of US pharma list

The London-based firm has also failed to increase market share for its next-gen versions of Advair - namely Breo, Ellipta and Anoro Ellipta - which had combined sales last year of

Latest news

GSK's Anoro first LAMA/LABA approved for COPD in US

Important step towards eventually replacing Seretide/Advair sales. GlaxoSmithKline's (GSK) chronic obstructive pulmonary disease (COPD) portfolio received a significant boost yesterday with the US approval of combination product Anoro Ellipta.
GSK’s COPD drug Anoro under review in US

FDA accepts new drug application for the LAMA/LABA combination. GlaxoSmithKline's (GSK) investigational respiratory treatment Anoro is under review by the FDA after the US regulator accepted its new drug ... The US submission follows Anoro's filing with

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

NICE – but not enough

Figure 2 shows the sales of GSK’s respiratory treatment, Anoro Ellipta, across the various availabilities. ... The chart reveals that Anoro Ellipta gets most sales when availability is unrestricted.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Theravance hires BMS veteran Pasqualone

Pasqualone joins Theravance as the company at a crucial time as its development deals with GlaxoSmithKline bears fruit with US approval of respiratory treatment Anoro Ellipta.